Fezolinetant
- Generic Name
- Fezolinetant
- Brand Names
- Veozah, Veoza
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15FN6OS
- CAS Number
- 1629229-37-3
- Unique Ingredient Identifier
- 83VNE45KXX
- Background
Vasomotor symptoms (VMS), more colloquially known as hot flashes or night sweats, are the most common symptoms, if not the cardinal symptoms, in women. With a median duration of 7.4 years, vasomotor symptoms are also the most common reasons why women seek treatments for menopausal issues. Although mostly considered a nuisance, vasomotor symptoms could potent...
- Indication
Fezolinetant is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.
- Associated Conditions
- Moderate to Severe Vasomotor Symptoms
- Associated Therapies
- -
A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04482270
- Locations
- πΊπΈ
Orlando Clinical Research Center, Orlando, Florida, United States
πΊπΈClinical Research of West Florida, Inc., Clearwater, Florida, United States
πΊπΈAmerican Research Corporation, San Antonio, Texas, United States
A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04476849
- Locations
- πΊπΈ
Clinical Research of West Florida, Inc., Clearwater, Florida, United States
πΊπΈClinical Pharmacology of Miami, LLC, Miami, Florida, United States
πΊπΈNational Institute of Clinical Research, Garden Grove, California, United States
A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT04451226
- Locations
- π¨π³
Site CN86012, Hangzhou, China
π¨π³Site CN86005, Hunan, China
π¨π³Site CN86037, Liuzhou, China
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 302
- Registration Number
- NCT04234204
- Locations
- π¨π³
Site CN86006, Guangzhou, China
π¨π³Site CN86025, Hangzhou, China
π¨π³Site CN86021, Shenzhen, China
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 501
- Registration Number
- NCT04003142
- Locations
- πΊπΈ
Comprehensive Clinical Development, West Palm Beach, Florida, United States
πΊπΈHwc Women's Research Center, Englewood, Ohio, United States
π¨π¦Site CA15002, Sherbrooke, Quebec, Canada
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 527
- Registration Number
- NCT04003155
- Locations
- πΊπΈ
National Research Institute - Panorama, Los Angeles, California, United States
πΊπΈEmerson Clinical Research Institute, Washington, District of Columbia, United States
πΊπΈAdvanced Clinical Research - Rancho Paseo, Banning, California, United States
A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1831
- Registration Number
- NCT04003389
- Locations
- πΊπΈ
Neuro-Behavioral Clinical Research, Inc, North Canton, Ohio, United States
πΊπΈAventiv Research, Inc., Columbus, Ohio, United States
πΊπΈComplete Healthcare For Women, Columbus, Ohio, United States
A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 356
- Registration Number
- NCT03192176
- Locations
- πΊπΈ
Research Site 052, Sacramento, California, United States
πΊπΈResearch Site 058, Sacramento, California, United States
πΊπΈResearch Site, Spokane, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.